Wellington Partners
AMBOSS has secured €30 million in Series B funding led by Partech’s growth fund, with Target Global acting as a co-investor. Existing investors Cherry Ventures, Wellington Partners and Holtzbrinck Digital also participated in the new financing round. With the new funding, AMBOSS will accelerate the global rollout of its knowledge platform and further invest in its smart guidance application to improve daily clinical decision-making for both generalist and specialist doctors.
iOmx Therapeutics announced today the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the company’s proprietary, high-throughput genetic screening platform, iOTarg™. iOTarg is designed to broadly screen tumor cells for hijacked immune checkpoints, which enable targeting of the tumor´s immune resistance mechanisms.
STipe Therapeutics, a company founded to exploit a novel approach to the stimulator of interferon genes (STING) Pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders, launched today with an EUR 20 million Series A financing. The round was co-led by Novo Holdings and Arix Bioscience plc who were joined by Wellington Partners Life Science V Fund and Sunstone Life Science Ventures A/S.
Page 3 of 25
